DCM
ELV icon

Deuterium Capital Management’s Elevance Health ELV Stock Holding History

Deuterium Capital Management’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-460
Closed -$222K – 42
2022
Q2 		$222K Sell
460
-750
-62% -$371K 0.75% 31
2022
Q1 		$594K Buy
+1,210
New +$553K 0.76% 22

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Deuterium Capital Management's ELV Position: Q3 2022 in Review

Deuterium Capital Management sold out of Elevance Health (ELV) in Q3 2022, closing a stake of 460 shares — an estimated $222K sold.

Deuterium Capital Management first reported a position in ELV in Q1 2022 and held it in 2 quarters. The position peaked at $594K in Q1 2022. 1,446 funds tracked by Wall St. Rank hold ELV as of Q3 2022.

  • Deuterium Capital Management reported no remaining Elevance Health position as of Q3 2022 after selling out during the quarter.
  • Deuterium Capital Management sold 460 Elevance Health shares in Q3 2022, an estimated $222K.
  • Deuterium Capital Management first reported a position in Elevance Health in Q1 2022 and held it in 2 quarters.
  • Deuterium Capital Management's Elevance Health position peaked at $594K in Q1 2022.
  • 1,446 funds tracked by Wall St. Rank held Elevance Health as of Q3 2022.

Based on Deuterium Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.